Detalhe da pesquisa
1.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol
; 170: 186-194, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706645
2.
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Gynecol Oncol
; 166(3): 389-396, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902297
3.
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Gynecol Oncol
; 164(1): 18-26, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34696892
4.
Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer.
Eur J Nucl Med Mol Imaging
; 48(6): 1998-2008, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33221969
5.
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Gynecol Oncol
; 159(1): 256-263, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32712155
6.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Breast Cancer Res
; 19(1): 98, 2017 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28830573
7.
A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.
Support Care Cancer
; 21(7): 1947-54, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23420555
8.
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Breast
; 54: 256-263, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33188992
9.
GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Anticancer Res
; 40(7): 3939-3945, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32620635
10.
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.
NPJ Breast Cancer
; 3: 4, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28649644
11.
Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors.
Leuk Lymphoma
; 47(7): 1295-305, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16923560
12.
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
Oncotarget
; 7(47): 77358-77364, 2016 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27764800
13.
Pazopanib-induced posterior reversible encephalopathy syndrome with possible syndrome of inappropriate secretion of antidiuretic hormone: an incidental or pathophysiological association?
Neural Regen Res
; 15(6): 1166-1168, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31823899
14.
Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study.
Aging (Albany NY)
; 7(12): 1066-76, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26638179
15.
Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors.
Hematol Oncol
; 22(4): 143-58, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16134191